| | The Right LIMS for COVID-19 Research LabVantage COVID-19 LIMS keeps pace with increasing COVID-19 sample volumes and research studies. Learn how one research center uses extraction and testing workflows, CDC test methods, and more to fight the coronavirus pandemic. Download our report. |
'Positive news' on AstraZeneca's COVID-19 vaccine is imminent: report Moderna has started turning out COVID-19 vaccine doses for quick shipment if approved: CEO Median COVID-19 charges for commercial plans top $45,000: report Gilead's remdesivir rescued from 'scrapheap' by taxpayers, who deserve a better price: lawmaker Healthcare roundup: AMA President details practice PPE issues Biopharma roundup: Lupin idles plant after workers test positive; Nephron plots vaccine manufacturing scale-up New Insilico Medicine spinout to tackle longevity, COVID-19 UNC ties up with Google to launch mental health app for front-line workers Little-known Chinese firm builds $79M COVID-19 vaccine plant, eyes production next year OptumRx script volume declines in Q2 due to COVID-19 Nephron looks to break into COVID-19 vaccine territory with $216M investment Featured Story | By Nick Paul Taylor AstraZeneca and the University of Oxford are set to share “positive news” on their COVID-19 vaccine soon, according to a leading U.K. journalist. The update, which could come as soon as tomorrow, may shed light on how the front-runner vaccine fared in early clinical trials. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky Moderna and its partners in the federal government are just now gearing up for a late-stage COVID-19 vaccine trial set to launch later this month. But at the same time, the mRNA biotech is prepping a supply of doses for quick shipment if the shot gets an FDA go-ahead. read more By Paige Minemyer A new study offers a look at the cost of COVID-19 hospitalizations and where patients are most likely to present with the virus. read more By Eric Sagonowsky Gilead Science’s remdesivir is on the very short list of drugs that have posted positive data in COVID-19, but one U.S. lawmaker is joining a chorus arguing the company priced the medicine too high. Taxpayers spent nearly $100 million to save the drug from the "scrapheap," the lawmaker wrote, and are being repaid with "price gouging." read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The FDA released a breakdown of its Coronavirus Treatment Accelerator Program, laying out its review process, regulatory milestones and more. A chance meeting led to a fat government contract for ApiJect and its as-yet-unapproved injector devices. And India-based generics maker Lupin was forced to idle a plant to quash an outbreak there. read more By Ben Adams A new biotech has come out of stealth mode with a funding round that includes “celebrity investors in artificial intelligence” as it aims to tackle aging and perhaps even COVID-19. read more By Heather Landi UNC officials are partnering with Google on an app to help healthcare workers find support amid the COVID-19 pandemic—and help health systems identify and proactively reach out to help units where more worker support is needed. read more By Angus Liu No animal data, no word on the timeline for a clinical trial, yet one little-known Chinese company is already building a multimillion-dollar facility for a COVID-19 vaccine late-comer, even as several domestic programs are already in final stages of clinical testing. read more By Paige Minemyer UnitedHealth Group reported $6.6 billion in profit for the second quarter, beating Wall Street projections. read more By Kyle Blankenship As major drugmakers crusade for a COVID-19 vaccine, the problem of securing enough manufacturing capacity for global distribution has grown more acute. Seeing a future opportunity, one U.S. generics maker is making a big down payment to boost its own shot offerings. read more |
